Neuroprotective Effect of Swertiamarin in a Rotenone Model of Parkinson’s Disease: Role of Neuroinflammation and Alpha-Synuclein Accumulation

Correction to: Intranasal Exposure to Low-Dose Rotenone Induced Alpha-Synuclein Accumulation and Parkinson’s Like Symptoms Without Loss of Dopaminergic Neurons

(2022) Monika Sharma et al.   NEUROTOXICITY RESEARCH

Swertiamarin from Enicostemma littorale, counteracts PD associated neurotoxicity via enhancement α-synuclein suppressive genes and SKN-1/NRF-2 activation through MAPK pathway

(2021) Taruna Pandey et al.   BIOORGANIC CHEMISTRY

Chemistry, Pharmacology and Therapeutic Potential of Swertiamarin – A Promising Natural Lead for New Drug Discovery and Development

(2021) Nur Sakinah Muhamad Fadzil et al.   Drug Design Development and Therapy

Modeling Parkinson’s Disease With the Alpha-Synuclein Protein

(2020) Mónica Gómez-Benito et al.   Frontiers in Pharmacology

Glial cells in Parkinson´s disease: protective or deleterious?

(2020) Ana V. Domingues et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Differential effects of vagus nerve stimulation paradigms guide clinical development for Parkinson’s disease

(2020) Ariana Q. Farrand et al.   Brain Stimulation

Neuroprotective Effect of Swertiamain on Cerebral Ischemia/Reperfusion Injury by Inducing the Nrf2 Protective Pathway

(2019) Hui Wang et al.   ACS Chemical Neuroscience

A natural AKT inhibitor swertiamarin targets AKT‐PH domain, inhibits downstream signaling, and alleviates inflammation

(2019) Man Zhang et al.   FEBS Journal

Effects of Exercise on Non-motor Symptoms in Parkinson’s Disease

(2018) Amy W. Amara et al.   CLINICAL THERAPEUTICS

Effect of moxibustion on mTOR-mediated autophagy in rotenone-induced Parkinson's disease model rats

(2018) Jun Ma et al.   Neural Regeneration Research

Anti-Inflammatory and Neuroprotective Role of Natural Product Securinine in Activated Glial Cells: Implications for Parkinson’s Disease

(2017) Dmitri Leonoudakis et al.   MEDIATORS OF INFLAMMATION

Anti-inflammatory activity of compounds isolated from Swertia mussotii

(2017) Yuan Xiang et al.   NATURAL PRODUCT RESEARCH

Anticonvulsant Effect of Swertiamarin Against Pilocarpine-Induced Seizures in Adult Male Mice

(2017) Xian-Hua Deng et al.   NEUROCHEMICAL RESEARCH

Motor and Non-Motor Symptoms in Parkinson’s Disease: Effects on Quality of Life

(2017) Elif GOKCAL et al.   Noropsikiyatri Arsivi-Archives of Neuropsychiatry

Gut–brain and brain–gut axis in Parkinson's disease models: Effects of a uridine and fish oil diet

(2017) Paula Perez-Pardo et al.   NUTRITIONAL NEUROSCIENCE

An update on the diagnosis and treatment of Parkinson disease

(2016) Philippe Rizek et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Neuroprotective and anti-inflammatory effects of morin in a murine model of Parkinson's disease

(2016) Kyung Moon Lee et al.   JOURNAL OF NEUROSCIENCE RESEARCH

A quantitative 1H nuclear magnetic resonance (qHNMR) method for assessing the purity of iridoids and secoiridoids

(2015) Zeyun Li et al.   FITOTERAPIA

Swertiamarin attenuates inflammation mediators via modulating NF-κB/I κB and JAK2/STAT3 transcription factors in adjuvant induced arthritis

(2014) S. Saravanan et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Neuroprotection by valproic acid in an intrastriatal rotenone model of Parkinson’s disease

(2014) C.H. Carriere et al.   NEUROSCIENCE

Environmental Toxins and Parkinson's Disease

(2013) Samuel M. Goldman   Annual Review of Pharmacology and Toxicology

Inhibition of Src tyrosine kinase activity by squamosamide derivative FLZ attenuates neuroinflammation in both in vivo and in vitro Parkinson's disease models

(2013) Wenjiao Tai et al.   NEUROPHARMACOLOGY

Rotenone Upregulates Alpha-Synuclein and Myocyte Enhancer Factor 2D Independently from Lysosomal Degradation Inhibition

(2013) Gessica Sala et al.   Biomed Research International

Further characterisation of the LPS model of Parkinson’s disease: A comparison of intra-nigral and intra-striatal lipopolysaccharide administration on motor function, microgliosis and nigrostriatal neurodegeneration in the rat

(2012) Deirdre B. Hoban et al.   BRAIN BEHAVIOR AND IMMUNITY

Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson’s disease

(2012) Anamitra Ghosh et al.   Journal of Neuroinflammation

Anti-diabetic Activity of Swertiamarin is due to an Active Metabolite, Gentianine, that Upregulates PPAR-γ Gene Expression in 3T3-L1 cells

(2012) Hitesh Vaidya et al.   PHYTOTHERAPY RESEARCH

Characterisation of a novel model of Parkinson's disease by intra-striatal infusion of the pesticide rotenone

(2011) P. Mulcahy et al.   NEUROSCIENCE

Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a progressive Parkinson's disease model

(2011) A.R. Carta et al.   NEUROSCIENCE

Characterisation of behavioural and neurodegenerative changes induced by intranigral 6-hydroxydopamine lesions in a mouse model of Parkinson’s disease

(2010) Shane Grealish et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

A rotarod test for evaluation of motor skill learning

(2010) Hiromi Shiotsuki et al.   JOURNAL OF NEUROSCIENCE METHODS

Neuroinflammation in Parkinson's disease: a target for neuroprotection?

(2009) Etienne C Hirsch et al.   LANCET NEUROLOGY

PPAR: a therapeutic target in Parkinsons disease

(2008) Rajnish K. Chaturvedi et al.   JOURNAL OF NEUROCHEMISTRY

Antinociceptive activity of swertiamarin isolated from Enicostemma axillare

(2008) V. Jaishree et al.   PHYTOMEDICINE

Antiedematogenic and Free Radical Scavenging Activity of Swertiamarin Isolated fromEnicostemma axillare

(2008) Jaishree Vaijanathappa et al.   PLANTA MEDICA

Glial reactions in Parkinson's disease

(2007) Patrick L. McGeer et al.   MOVEMENT DISORDERS